Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3
Monocentric, Randomized, Subject and Rater Blinded Clinical Investigation to Prove the Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3 Containing Lidocaine - After Single Injection for Correction of Nasolabial Folds (NLF)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Frankfurt am Main, Germany, 60311
- Praxisklinik Kaiserplatz
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject with bilateral, symmetrical NLF and wish for correction. Documented severity of NLF score 2 or 3 at screening on the Merz Wrinkle Severity Rating Scale II
Exclusion Criteria:
- Any severe or uncontrolled systemic disease (e.g. cardiac, renal, pulmonary, hepatic, or gastrointestinal). Subject suffering from diabetes mellitus, autoimmune and rheumatic diseases, clinically relevant coagulation disorders, recurrent angina, or severe psychic, neurological or mental disease
- History of malignancy within the last 5 years before the study
- Infection, inflammations or active dermatological disease in the face
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hyaluronic Acid Filler - Medical Device
|
The dosage is individualized depending on the depth of the NLF.
The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively.
Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design.
The allocation of fillers to the side of the face will be randomized.
The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The proportion of subjects reporting an equal or better outcome for the side of face treated with Belotero® Basic compared to the side of face treated with Juvéderm® Ultra 3 at V4 on the validated Wrinkle Severity Rating Scale II
Time Frame: Week 4
|
Week 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall intra-individual change at V2 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation
Time Frame: Week 0
|
Week 0
|
|
Overall intra-individual change at V3 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation
Time Frame: 2 Weeks
|
2 Weeks
|
|
Overall intra-individual change at V4 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation
Time Frame: 4 Weeks
|
4 Weeks
|
|
Overall absolute score change at V2 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation assessed by photo rating of one independent rater
Time Frame: Week 0
|
Week 0
|
|
Overall absolute score change at V3 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation assessed by photo rating of one independent rater
Time Frame: 2 Weeks
|
2 Weeks
|
|
Overall absolute score change at V4 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation assessed by photo rating of one independent rater
Time Frame: 4 Weeks
|
4 Weeks
|
|
Proportion of overall responders i.e. at least 1 point improvement in the validated Wrinkle Severity Rating Scale II(WSRS II) at V4, based on the intra-individual change in WSRS II compared to baseline before implantation, V2 pre implantation
Time Frame: 4 Weeks
|
4 Weeks
|
|
Assessment of Global aesthetic improvement [GAIS] by the investigator and subject V2 post implantation and V4
Time Frame: 4 Weeks
|
4 Weeks
|
|
Overall GAIS by photo rating of an individual rater V2 post implantation and V4
Time Frame: 4 Weeks
|
4 Weeks
|
|
Subject Satisfaction Questionnaire results at V2 pre and post implantation
Time Frame: Week 0
|
Week 0
|
|
Subject Satisfaction Questionnaire results at V3
Time Frame: 2 Weeks
|
2 Weeks
|
|
Subject Satisfaction Questionnaire results at V4
Time Frame: 4 Weeks
|
4 Weeks
|
|
Global assessment of subject comfort at V2 post implantation by the investigator and the subject.
Time Frame: Week 0
|
Week 0
|
|
Global assessment of subject comfort at V3 by the investigator and the subject
Time Frame: 2 Weeks
|
2 Weeks
|
|
Global assessment of subject comfort at V4 by the investigator and the subject
Time Frame: 4 Weeks
|
4 Weeks
|
|
Proportion of subjects feeling the implant at V2 post implantation
Time Frame: Week 0
|
Week 0
|
|
Proportion of subjects feeling the implant at V3.
Time Frame: 2 Weeks
|
2 Weeks
|
|
Proportion of subjects feeling the implant at V4
Time Frame: 4 Weeks
|
4 Weeks
|
|
Proportion of subjects recommending Belotero® Basic only or Juvéderm® Ultra 3 only or both at V4
Time Frame: 4 Weeks
|
4 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clemens Acker, Dr., Merz Pharmaceuticals GmbH
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MRZ 90028_4007_0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.